PARP14 and cancer: This study indicates that PARP14 inhibition and other undiscovered gene mutations beyond BRCA1/2 deficiency might hamper the homologous recombination repair pathway, making cancer cells more susceptible to DNA lesions (Nicolae et al., 2015).